Cabaletta Bio, Inc.
General ticker "CABA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $308.4M (TTM average)
Cabaletta Bio, Inc. follows the US Stock Market performance with the rate: 26.2%.
Estimated limits based on current volatility of 3.0%: low 1.85$, high 1.97$
Factors to consider:
- Total employees count: 156 (-4.9%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Commercialization failure, Regulatory and compliance, Manufacturing scale up, Clinical trial failure, Inability to raise capital
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.37$, 3.80$]
- 2026-12-31 to 2027-12-31 estimated range: [1.43$, 3.82$]
Financial Metrics affecting the CABA estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Net income
- Positive: 58.56 < Shareholder equity ratio, % of 67.88 <= 69.38
- Positive: Interest expense per share per price, % of 0.88 <= 1.42
- Negative: negative Operating cash flow
Short-term CABA quotes
Long-term CABA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $74.66MM | $125.14MM | $172.24MM |
| Operating Income | $-74.66MM | $-125.14MM | $-172.24MM |
| Non-Operating Income | $6.99MM | $9.28MM | $4.38MM |
| Interest Expense | $0.00MM | $0.75MM | $2.00MM |
| R&D Expense | $55.42MM | $97.20MM | $142.67MM |
| Income(Loss) | $-67.67MM | $-115.86MM | $-167.86MM |
| Net Income(Loss)* | $-67.67MM | $-115.86MM | $-167.86MM |
| Stockholders Equity | $236.20MM | $152.34MM | $112.05MM |
| Assets | $253.65MM | $185.05MM | $165.08MM |
| Operating Cash Flow | $-53.55MM | $-88.22MM | $-131.08MM |
| Capital expenditure | $0.69MM | $2.21MM | $1.23MM |
| Investing Cash Flow | $-22.45MM | $47.29MM | $-50.27MM |
| Financing Cash Flow | $187.63MM | $11.68MM | $100.35MM |
| Earnings Per Share** | $-1.65 | $-2.34 | $-1.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.